Figure Legends
FIGURE 1. Histological and immunohistochemical features of our patient
with OMS-NB.
(A) Multiple lymphoid follicles (arrowhead) are present in the
neuroblastoma tissue (hematoxylin and eosin staining; x4). (B) High
magnification image of lymphoid follicle in neuroblastoma tissue
(hematoxylin and eosin staining; x200). (C) Lymphoid follicle stained
with CD3 monoclonal antibody. Sparse CD3-positive cells are visible in
the germinal center, follicular mantle and interstitium (peroxidase
staining; x100). (D) Lymphoid follicle stained with CD20 antibody.
CD20-positive cells are concentrated in the germinal center and
follicular mantle (peroxidase staining; x100). (E) Lymphoid follicle
stained with CD21 monoclonal antibody. CD21-positive cells are
concentrated in the germinal center (peroxidase staining; x100). OMS-NB,
Opsoclonus-myoclonus syndrome associated with neuroblastoma.
FIGURE 2. DEX pulse and IVIg treatment effect on OMS Rating Scales and
CSF data.
Severity of OMS symptoms was evaluated using OMS Rating Scales, as
previously reported. [8] The OMS Rating Scales evaluate six
symptoms: stance, gait, arm function, opsoclonus, mood/behavior and
speech. Each symptom is scored from 0 to 3 for increasing severity, then
the total score is evaluated. Our patient was too young to be speaking,
therefore we evaluated five symptoms (excluding speech) for the OMS
Rating Scales score. B-cell ratio in CSF means the ratio of B cells to
total cells in CSF. DEX, dexamethasone; IVIg, intravenous
immunoglobulin; OMS, Opsoclonus-myoclonus syndrome; CSF, cerebrospinal
fluid.